The Global Pneumococcal
Vaccines Market, by Vaccine Type (PCV10, PCV13, and PPSV23), by
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online
Pharmacies) was valued at US$ 7,376.6 million in 2018 and is projected to
exhibit a CAGR of 7.5% over the forecast period (2018 - 2026).
Healthcare facilities are looking forward to
expand their facilities with advanced technologies to create innovative and
cost-effective solutions to address barriers to universal vaccination For
instance, in April 2016, Glaxo Smith Kline (GSK) and Vodafone collaborated to
provide smartphones with an app to various healthcare facilities in northern
Mozambique, Africa for a period of one year. The program received funds from
GAVI and United States Agency for International Development (USAID) under
mVacciNation pilot program. The app enables these healthcare facilities to
report regularly on vaccine stock levels and refrigerator temperatures, thereby
improving critical supply chain and cold chain management. Furthermore, it
helps health workers to register patients, view their vaccination histories,
and also allows to send reminders to registered patients for their next
vaccination.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2295
Browse 26 Market Data Tables and
32 Figures spread through 150 Pages and in-depth TOC on "Pneumococcal
Vaccines Market, by Vaccine Type (PCV10, PCV13, and PPSV23), by Distribution
Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) -
Global Forecast to 2026"
Increasing collaborations among
key players to develop and introduce new pneumococcal vaccines and ongoing
clinical trial studies on pneumococcal vaccine are expected to drive growth of
the pneumococcal vaccines market. For instance, in April 2018, Merck & Co,
Inc. initiated two Phase III studies of PCV-15 (V114), an investigational
polyvalent conjugate vaccine for the prevention of pneumococcal disease.
Furthermore, in February 2017, Astellas Pharma Inc. and Affinivax, Inc. signed
an exclusive worldwide license agreement to develop and commercialize a vaccine
targeting Streptococcus pneumoniae. This partnership would utilize Affinivax’s
proprietary vaccine technology platform – Multiple Antigen Presenting System
(MAPS) to develop a novel vaccine.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/pneumococcal-vaccines-market-2295
Key Takeaways of the Pneumococcal
Vaccines Market:
The global pneumococcal vaccines
market is expected to witness a CAGR of 7.5% during the forecast period, owing
to increasing research and development activities to introduce novel vaccines.
Increasing adoption of PCV13
vaccine, especially for adult and pediatric indication, results in the
vaccine’s increasing demand in various emerging economies. Therefore, this
segment is expected to account for major revenue share in pneumococcal vaccines
market over the forecast period. According to the United Nations Children's
Fund (UNICEF), in 2016, around 74 million doses of PCV13 were supplied, with an
increase by 7.5% as compared to 2015 globally (67 million doses).
Major players operating in the
global pneumococcal vaccines market include, Pfizer, Inc., Merck & Co.
Inc., and GlaxoSmithKline plc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2295
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment